Lv3
240 积分 2025-04-20 加入
Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough
19天前
已完结
Response in Patient-reported Cough Severity in Soothe, a Phase 2b Trial of Camlipixant in Refractory Chronic Cough
19天前
已完结
Improvements in Cough Frequency Over 24 Hours with BLU-5937, a Selective P2X3 Antagonist, in Patient Subgroups Defined by Baseline Awake Cough Frequencies
19天前
已完结
Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough
19天前
已完结
The Efficacy of Superior Laryngeal Nerve Block for Neurogenic Cough: A Placebo‐Controlled Trial
19天前
已完结
Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease
19天前
已完结
Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis
19天前
已完结
Palliative vagatomy for nonresectable bronchogenic carcinoma
19天前
已关闭
Gefapixant for Refractory or Unexplained Chronic Cough?
19天前
已完结
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
19天前
已完结
皖公网安备34019202002308
